Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate

Urology

Volumn 68, Issue 6, 2006, Pages 1237-1241

  Quan, Aimee L ^a   Ciezki, Jay P ^a   Reddy, Chandana A ^a   Angermeier, Kenneth ^a   Ulchaker, James ^a   Mahadevan, Arul ^a   Chehade, Nabil ^b   Altman, Andrew ^b   De Oreo, Gerard ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORGAN WEIGHT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; REFERENCE DATABASE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33845348184     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.08.1095     Document Type: Article

References (14)

1. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal placement brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
2. Merrick G.S., Wallner K.E., and Butler W.M. Patient selection for prostate brachytherapy: more myth than fact. Oncology 18 (2004) 445-457
3. Lee W.R. The role of androgen deprivation therapy with prostate brachytherapy. Urology 60 (2002) 39-44
4. Merrick G.S., Wallner K.E., and Butler W.M. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 169 (2003) 1643-1652
5. Albertson P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 (2005) 1248-1253
6. McNeely L.K., Stone N.N., Presser J., et al. Influence of prostate volume on dosimetry results in real-time I-125 seed implantation. Int J Radiat Oncol Biol Phys 58 (2004) 292-299
7. Lehrer S., Stone N.N., and Stock R.G. Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy. J Urol 173 (2005) 79-81
8. Nag S., Bice W., DeWyngaert J.K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230
9. Cox J., Grignon D., Kaplan R., et al. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
10. Elshaikh M.A., Angermeier K., Ulchaker J., et al. The effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology 61 (2003) 152-155
11. Butler W.M., and Merrick G.S. Myths and fallacies in permanent prostate brachytherapy. Med Dosim 28 (2003) 155-165
12. Koutrouvelis P.G., Lailas N., Katz S., et al. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup. J Urol 169 (2003) 1331-1336
13. Ciezki J.P., Klein E.A., Angermeier K., et al. A retrospective comparison of the use of androgen deprivation among low and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys 60 (2004) 1347-1350
14. Elshaikh M.A., Ulchaker J., Reddy C.A., et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate I-125 brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized trial. Int J Radiat Oncol Biol Phys 62 (2005) 164-169